$AMGN A big week ahead for Amgen, now it's found a bottom. Amgen will present data from its oncology pipeline at the 55th Annual Meeting of the American Society of Clinical Oncology that begins on May 31. This Could a hugely significant day for NASDAQ:AMGN which is in need of some good news to reassure investors. They stock has been on a terrible run lately but it may now have found a bottom, ready to move higher as the entire sector sell-off has left these companies at very attractive P/E ratios, offering stability and cash generation at a time when tech is in the wars.
RECENT DEVELOPMENTS
Amgen (NASDAQ:AMGN) has made a cash offer of SEK 1,610 (US$167M) for Copenhagen-based Nuevolution AB, a developer of small molecule therapeutics in inflammation, oncology and immuno-oncology utilizing its drug discovery platform called Chemetics.
AVERAGE ANALYSTS PRICE TARGET $206
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
12 BUY
1 OVERWEIGHT
1 2 HOLD
P/E RATIO 13.66
COMPANY PROFILE
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA.
AMGN trade ideas
Amgen Ready for a ReboundOn a graphical level, a bullish divergence has formed between the price and the Commodity Channel Index (CCI). A close above the black trendline will give the entry signal (long) on Amgen.
First target area $ 179.65/182.47, while the stop loss below the last low ($ 168.44). I leave you free to decide the level on the basis of your money management.
$AMGN Good results might not be good enough. Cautious.Despite FDA approval for Amgen's new Enrel drug last week we see the bounce as the formation of a bear flag heading into earnings. Sentiment is so poor in the sector we fear that regardless of results the stock will eventually continue to drop. Amgen is very cheap at 14 P/E ratio with an average rating of HOLD among 25 analysts covering the name.
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate and Parsabiv.